Mylan and Biocon have launched their pegfilgrastim biosimilar, Fulphila, in Canada for the treatment of febrile neutropenia, a condition of low white blood cell count, as a result of chemotherapy.
Mylan and Biocon said they have launched their pegfilgrastim biosimilar (Fulphila) in Canada for the treatment of febrile neutropenia, a condition of low white blood cell count, for patients receiving myelosuppressive antineoplastic drugs as part of chemotherapy.
“As a global leader in the development of complex products, including biosimilar medicines, Mylan is proud to launch Fulphila in Canada,” said Mylan Canada Country Manager David Simpson in a release.
Mylan and Biocon said the Canadian approval for Fulphila was based on an analysis of nonclinical and clinical data, which confirmed biosimilarity to reference pegfilgrastim, Neulasta, and showed no clinically meaningful differences in terms of safety and efficacy.
“We have reached a negotiated agreement with the Pan-Canadian Pharmaceutical Alliance to help expand access to treatment and reduce costs” for patients with cancer, Simpson said.
More on the Mylan/Biocon Partnership
Mylan and Biocon have also produced the trastuzumab biosimilar (Ogivri), referencing Herceptin. Ogivri was launched in the United States late in 2019. It is also approved for marketing in Canada. The 2 companies have a pipeline of 11 biologic products under development for the global market.
“With Mylan's global portfolio of 20 biosimilar and insulin analog products in development or on the market, we are bringing vast biosimilars experience to the market here in Canada. Among these products is an extensive oncology portfolio increasing choice and access for patients across the region," Simpson said.
Fulphila Around the World
Currently, Fulphila is marketed in the United States and, as of earlier this month, Australia. Fulphila received marketing approval from the European Medicines Agency in late 2018.
Mylan has exclusive commercialization rights for Fulphila in the United States, Canada, Japan, Australia, New Zealand, and the European Union and European Free Trade Association countries.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.